CMS also said that removed records would not be included in the initial public release of data on September 30th. Instead, removed records will be returned to manufacturers and GPOs for further remediation consistent with the revised requirements. Given that this is the first reporting period for Open Payments, we expected there to be some issues, but this latest issue came as quite a surprise, said Tim Robinson, Chief Knowledge Office at MMIS. There have been challenges with the CMS site and unexpected removal of data that was submitted in accordance with previously published requirements. MMIS will provide detailed instructions on how to access the cloud-based MediSpend Validate portal early next week. Open Payments, a program designed to bring more transparency to the healthcare industry, is struggling due to technology issues related to data matching, but physician data is complex and we expected some of these problems." commented Daboul. As a recognized technology leader in the aggregate spend marketplace, making MediSpend Validate available to all, is the right thing to do. About MMIS | MediSpend Since 1999, MMIS has developed innovative products and services for the life sciences industry. The MediSpend Global Compliance platform is recognized as a leading SaaS solution that allows organizations to cost-effectively comply with global transparency laws, manage risk and securely communicate with healthcare providers across the globe. Other offerings include MediSpend Insight, dashboards providing business insight to manage risk and its business impact. In addition, MMIS operates the Physicians Professional Network (PPN), a cloud-based portal for licensed healthcare professionals that allows them to review and dispute spend data from multiple companies in a secure and private environment.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/mmis-offers-medispend-validate-tool-210300488.html
Medical Couriers in the US Industry Market Research Report from IBISWorld Has Been Updated
Treatment responders from these studies were again randomized to continue treatment with placebo or ixekizumab for up to 60 weeks. Results from the studies revealed that ixekizumab was statistically superior to both Enbrel and placebo on all skin clearance measures. Moreover, the company stated in its press release that the study has met all key objectives. Based on the positive results the company plans to file for ixekizumab in the first half of 2015. Though the results on ixekizumab were encouraging, the psoriasis market is highly crowded with the presence of companies like Johnson & Johnson ( JNJ ) among others. Moreover, several companies have late-stage candidates in development for psoriasis.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/eli-lilly-uncovers-positive-data-204502556.html
Eli Lilly Uncovers Positive Data from Ixekizumab Studies - Yahoo Finance
announces bid to purchase shares Imperial Equities Inc. 3 hours ago 0 shares Content preferences Done EDMONTON , Aug. 22, 2014 /CNW/ -Imperial Equities Inc. ( IEI.V ) today announced that it intends to make a Normal Course Issuer Bid through the facilities of and in accordance to the by-laws and rules of the Toronto Venture Exchange to be transacted through the facilities of the TSX and other Canadian market places.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/imperial-equities-inc-announces-bid-153500641.html
Imperial Equities Inc. announces bid to purchase shares - Yahoo Finance
Healthcare utilization rates will grow at a faster rate than in the previous five years, as the Patient Protection and Affordable Care Act increases the number of individuals with healthcare coverage, says Carusotto. As a result, IBISWorld expects industry revenue to grow at an annualized rate in the five years to 2019. While demand for industry services will increase, competition from the general courier industry is expected to intensify as companies such as FedEx continue their push into the healthcare transport space. For more information, visit IBISWorlds Medical Couriers in the US industry report page. Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189 IBISWorld industry Report Key Topics Medical couriers deliver medical equipment to patients and healthcare providers, and they deliver specimens to medical laboratories for testing. Some medical couriers carry donor organs and recipient patients to hospitals. Couriers are distinguished from other medical distributors by features such as speed, security, tracking, specialization and individualization of services.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/08/prweb12112567.htm